HuM&C KRX:263920KOSDAQ
휴엠앤씨 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days10
DART filings, 7 days2
Articles tracked11since Sep 11
In Q3 2026, HuM&C reported revenue of ₩15.0bn, up 11.9% year on year, and operating profit of ₩1.0bn. HuM&C (휴엠앤씨) appeared in 10 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Nov 13 with 10 articles. The most common catalyst was earnings (5). It was most often mentioned alongside GC Biopharma and Daewon Pharmaceutical.
Filing signals High dividend Screener
HuM&C quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩15.0bn | +11.9% | ₩1.0bn margin 6.8% | ₩94m |
| Q2 2026 | ₩15.7bn | +16.8% | ₩1.2bn margin 7.9% | ₩976m |
| Q1 2026 | ₩14.5bn | +15.8% | ₩823m margin 5.7% | ₩905m |
| Q4 2025 derived | ₩13.0bn | +2.4% | ₩464m margin 3.6% | ₩640m |
| Q3 2025 | ₩13.4bn | +15.9% | ₩730m margin 5.5% | ₩664m |
| Q2 2025 | ₩13.4bn | +21.8% | ₩777m margin 5.8% | −₩34m |
| Q1 2025 | ₩12.5bn | +4.4% | ₩512m margin 4.1% | ₩302m |
| Q4 2024 derived | ₩12.7bn | +12.1% | ₩1.1bn margin 8.6% | −₩30m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
HuM&C top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest HuM&C news Korean headlines
-
HueMNC Q3 sales 15 billion won, operating profit 1 billion won, up 12% and 40% year-on-year respectively
2 more on this story · 2 outlets